| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Aging and the Growth of Long-Term Care |
0 |
0 |
0 |
243 |
0 |
8 |
22 |
1,315 |
| Aging and the Growth of Long-Term Care |
1 |
1 |
1 |
31 |
1 |
3 |
8 |
152 |
| An Economic Evaluation of the War on Cancer |
0 |
0 |
0 |
97 |
1 |
3 |
14 |
375 |
| Are the Young Becoming More Disabled? |
0 |
0 |
0 |
93 |
0 |
0 |
9 |
355 |
| Catastrophe Bonds, Reinsurance, and the Optimal Collateralization of Risk-Transfer |
0 |
0 |
1 |
153 |
1 |
3 |
19 |
563 |
| Does Medicare Benefit the Poor? New Answers to an Old Question |
0 |
0 |
0 |
67 |
0 |
2 |
9 |
388 |
| Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? |
0 |
0 |
0 |
85 |
0 |
2 |
10 |
45 |
| Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes? |
0 |
0 |
0 |
23 |
0 |
4 |
13 |
49 |
| Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey |
0 |
0 |
0 |
55 |
0 |
1 |
9 |
266 |
| Effects of Expanding Health Screening on Treatment - What Should We Expect? What Can We Learn? |
0 |
0 |
0 |
6 |
2 |
3 |
21 |
65 |
| Effects of expanding health screening on treatment – What should we expect? What can we learn? |
0 |
0 |
0 |
6 |
0 |
5 |
13 |
68 |
| Evaluation of Medical Technologies with Uncertain Benefits |
0 |
0 |
1 |
49 |
0 |
1 |
7 |
52 |
| Food Prices and the Dynamics of Body Weight |
0 |
0 |
0 |
71 |
0 |
3 |
12 |
244 |
| GLP-1 Therapy and the Reshaping of Socioeconomic Gradients in Health |
8 |
8 |
8 |
8 |
1 |
1 |
1 |
1 |
| HIV Breakthroughs and Risk Sexual Behavior |
0 |
0 |
0 |
84 |
0 |
1 |
10 |
645 |
| Healing the Poor: The Influence of Patient Socioeconomic Status on Physician Supply Responses |
0 |
0 |
0 |
13 |
2 |
2 |
15 |
68 |
| Health Insurance as a Two-Part Pricing Contract |
0 |
0 |
0 |
97 |
0 |
1 |
10 |
438 |
| Health and Access Effects of New Drugs: Combining Experimental and Non-Experimental Data |
0 |
0 |
0 |
52 |
0 |
2 |
10 |
201 |
| Insurance and Innovation in Health Care Markets |
0 |
0 |
1 |
139 |
1 |
3 |
23 |
492 |
| Insurance, Self-Protection, and the Economics of Terrorism |
0 |
0 |
0 |
289 |
3 |
5 |
16 |
904 |
| Insurer Bargaining and Negotiated Drug Prices in Medicare Part D |
0 |
0 |
0 |
32 |
0 |
3 |
19 |
168 |
| Insurers' Negotiating Leverage and the External Effects of Medicare Part D |
0 |
0 |
0 |
14 |
0 |
0 |
11 |
108 |
| Insurers’ Negotiating Leverage and the External Effects of Medicare Part D |
0 |
0 |
0 |
3 |
0 |
4 |
17 |
89 |
| Intellectual Property and Marketing |
0 |
0 |
0 |
0 |
1 |
1 |
10 |
16 |
| Intellectual Property and Marketing |
0 |
0 |
0 |
91 |
1 |
4 |
17 |
409 |
| International Differences in Longevity and Health and Their Economic Consequences |
0 |
0 |
0 |
35 |
0 |
2 |
12 |
134 |
| International Differences in Longevity and Health and their Economic Consequences |
0 |
0 |
0 |
55 |
3 |
8 |
21 |
191 |
| International Differences in Longevity and Health and their Economic Consequences |
0 |
0 |
0 |
51 |
0 |
1 |
6 |
270 |
| Mortality Risk, Insurance, and the Value of Life |
0 |
0 |
0 |
37 |
2 |
8 |
38 |
87 |
| Nonprofit Production |
0 |
0 |
0 |
0 |
0 |
3 |
8 |
204 |
| Nonprofit Production and Competition |
0 |
0 |
1 |
301 |
4 |
7 |
18 |
1,273 |
| Optimal Liability for Terrorism |
0 |
0 |
0 |
40 |
0 |
1 |
9 |
224 |
| Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D |
0 |
0 |
0 |
24 |
1 |
2 |
11 |
107 |
| Risk Preferences Over Health: Empirical Estimates and Implications for Healthcare Decision-Making |
0 |
0 |
0 |
15 |
0 |
4 |
15 |
24 |
| The Declining Quality of Teachers |
0 |
0 |
0 |
222 |
1 |
5 |
22 |
1,722 |
| The Effect of US COVID-19 Excess Mortality on Social Security Outlays |
0 |
0 |
0 |
6 |
1 |
4 |
24 |
29 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
89 |
1 |
4 |
15 |
387 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
492 |
0 |
1 |
19 |
1,622 |
| The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination |
0 |
0 |
0 |
0 |
0 |
1 |
14 |
19 |
| The Insurance Value of Medical Innovation |
0 |
0 |
0 |
34 |
0 |
5 |
15 |
122 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
0 |
3 |
0 |
2 |
8 |
779 |
| The Rise in Old Age Longevity and the Market for Long-Term Care |
0 |
0 |
0 |
234 |
0 |
2 |
12 |
1,788 |
| The Value of Medican and Pharmaceutical Interventions for Reducing Obesity |
0 |
0 |
0 |
29 |
0 |
3 |
14 |
179 |
| The Welfare Effects of Medical Malpractice Liability |
0 |
0 |
0 |
101 |
0 |
4 |
9 |
484 |
| The Welfare Effects of Public Drug Insurance |
0 |
0 |
1 |
78 |
1 |
2 |
16 |
303 |
| Time-Inconsistency and Welfare |
0 |
0 |
0 |
79 |
0 |
0 |
11 |
390 |
| Understanding Health Disparities Across Education Groups |
0 |
1 |
2 |
400 |
2 |
3 |
15 |
1,718 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
36 |
0 |
0 |
5 |
116 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
50 |
0 |
3 |
12 |
192 |
| Understanding the Economic Consequences of Shifting Trends in Population Health |
0 |
0 |
0 |
43 |
1 |
2 |
11 |
236 |
| Unintended Consequences of Products Liability: Evidence from the Pharmaceutical Market |
0 |
0 |
0 |
15 |
0 |
1 |
15 |
123 |
| Vaccine Allocation Priorities Using Disease Surveillance and Economic Data |
0 |
0 |
0 |
3 |
0 |
2 |
15 |
30 |
| Total Working Papers |
9 |
10 |
16 |
4,273 |
31 |
145 |
715 |
20,229 |
LogEc is hosted by the
Örebro University School of Business.